Considering that in humans between 29 and 57% of wild-type dystrophin could completely prevent muscular dystrophy when expressed in the majority of muscle fibres within the muscle28, the level of dystrophin correction we achieved with both approaches (around 50%) could be sufficient to provide a therapeutic benefit, if obtained in vivo. The gene discussed is DMD; the disease is muscular dystrophy.